XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Three SNPs showed a main association with advanced prostate cancer risk after multiple testing correction: catalase (CAT) rs511895, prostaglandin-endoperoxide synthase 2 (PTGS2) rs5275, and xeroderma pigmentosum group C (XPC) rs2228001.
|
29697282 |
2019 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
To quantitatively elucidate the genetic impact of the <i>XPC</i> rs2228000 and rs2228001 polymorphisms on the response to platinum-based chemotherapy, the present meta-analysis was conducted.
|
31190883 |
2019 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study has genotyped 334 subjects from North Indian population for xeroderma pigmentosum complementation Group C (XPC) rs2228001A>C, XPC rs77907221 polyadenylate (PAT) deletion/insertion (D/I), xeroderma pigmentosum complementation Group D - rs13181A>C, and xeroderma pigmentosum complementation Type G rs17655 G>C polymorphisms with polymerase chain reaction (PCR)-restriction-fragment length polymorphism or allele-specific PCR methods.
|
29893334 |
2018 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the second part we selected 2 common single nucleotide polymorphisms within genes involved in NER (Xeroderma pigmentosum group C (XPC) Lys939Gln, Xeroderma pigmentosum group D (XPD) Lys751Gln) to determine the relation between them and CRC risk.
|
29793654 |
2018 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
A total of 7 XPC tagging SNPs (tag-SNPs) were selected from the International HapMap Project Databases (rs2228001A/C, rs2470353G/C, rs2228000C/T, rs3731114C/G, rs3729587G/C, rs2607775C/G and rs3731055G/A) and were genotyped in 205 patients with PC and 230 non-cancer control subjects using a SNaPshot assay.
|
30344718 |
2018 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The purpose of this study was to evaluate the relationship between single-nucleotide polymorphism (SNP) rs2228001 in xeroderma pigmentosum group C (XPC), SNP rs4073 in interleukin 8 (IL8), and SNP rs2279744 in mouse double minute 2 (MDM2) homolog gene with PCa susceptibility.
|
26135929 |
2015 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interestingly, we found significant correlation between Lys939Gln genotypes and XPC mRNA expression for Asian populations as well.
|
24375193 |
2014 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis based on current evidences suggested that the XPC polymorphisms (Lys939Gln, Val499Arg, and PAT-/+) did not contribute to gastric cancer risk.
|
24886180 |
2014 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
A meta-analysis was performed to examine the association between XPC Lys939Gln polymorphism and susceptibility to bladder cancer (BC).
|
23269608 |
2013 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our meta-analysis suggested that the XPC Lys939Gln polymorphism contributed to the risk of urinary bladder cancer.
|
23819639 |
2013 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The current data suggested that XPC Ala499Val and Lys939Gln polymorphisms may contribute to the identification of patients with increased risk for BC.
|
22519360 |
2012 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The distributions of XPC Lys939Gln genotypes differed significantly between the response group (complete + partial responses) and the non-response group (stable + progressive disease; P = 0.022).
|
22166526 |
2010 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
To investigate the association between two Xeroderma pigmentosum group C polymorphism (XPC Lys939Gln and insertion/deletion PAT -/+ in intron 9) and bladder cancer (BC) susceptibility.
|
19924443 |
2010 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
These analyses suggest that XPC Lys(939)Gln, PAT+/- and Ala(499)Val likely contribute to susceptibility to cancers.
|
18771913 |
2008 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
We evaluated the association of two common non-synonymous polymorphisms in XPC (Ala499Val and Lys939Gln) with breast cancer risk in the Long Island Breast Cancer Study Project (LIBCSP), a population-based case-control study.
|
18053706 |
2008 |
XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder.
|
15886698 |
2005 |